Saioa Garcia-Longarte

Ms. Saioa Garcia-Longarte

CIC bioGUNE, Derio, Spain
orcid
Bioinformatician | PhD student - Cancer Cell Signaling and M...

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RGRaquel García-Vílchez
Raquel García-Vílchez
AAAna M. Añazco-Guenkova
Ana M. Añazco-Guenkova
SDSabine Dietmann
Sabine Dietmann
JLJudith López
Judith López
VMVirginia Morón-Calvente
Virginia Morón-Calvente
SBSandra Blanco
Sandra Blanco
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology.

14 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
AZAmaia Zabala-Letona
Amaia Zabala-Letona
MPMikel Pujana-Vaquerizo
Mikel Pujana-Vaquerizo
BMBelen Martinez-Laosa
Belen Martinez-Laosa
MPMaria Ponce-Rodriguez
Maria Ponce-Rodriguez
Saioa Garcia-LongarteSaioa Garcia-Longarte
Saioa Garcia-Longarte
ACArkaitz Carracedo
Arkaitz Carracedo
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1,2,3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding.

23 April 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ASAriane Schaub-Clerigué
Ariane Schaub-Clerigué
IHIvana Hermanova
Ivana Hermanova
APAinara Pintor-Rial
Ainara Pintor-Rial
MSMariia Sydorenko
Mariia Sydorenko
LVLorea Valcarcel-Jimenez
Lorea Valcarcel-Jimenez
VTVerónica Torrano
Verónica Torrano
Prostate cancer is the fifth cause of death by cancer worldwide, second in incidence in the male population. The definition of the molecular basis of its development and the oncogenic signals driving lethality continue to be important objectives in prostate cancer research. Prior work from others and us has demonstrated that loss of PGC1α expression results in a metabolic, signaling and transcriptional reprogramming that supports the development of metastatic disease. However, we do not fully understand the spectrum of tumor suppressive effects regulated by this co-regulator. Here we show that PGC1α governs non-cell autonomous paracrine tumor suppression in prostate cancer. A systematic analysis of the transcriptional landscapes associated to PGC1α loss of expression revealed that PGC1α alters the expression of genes encoding for secreted proteins. Cell secretome studies corroborated that PGC1α-dependent ERRα regulation in prostate cancer cells suppresses the growth of tumor cells exposed to their conditioned media, independently of androgen receptor status. The integration of in vitro and in vivo secretomics data and genetic perturbation assays revealed spermidine synthase as a transcriptional target of PGC1α and mediator of the paracrine metabolic growth suppressive effect. Moreover, the activity of the regulatory axis PGC1α-ERRα-SRM was reflected in patients and had prognostic value. Altogether, this work provides unprecedented evidence of the non-cell autonomous suppressive role of PGC1α, which broadens the view of this co-regulator as a multifactorial tumor suppressor in prostate cancer.

18 July 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JCJana R. Crespo
Jana R. Crespo
NMNatalia Martín-Martín
Natalia Martín-Martín
Saioa Garcia-LongarteSaioa Garcia-Longarte
Saioa Garcia-Longarte
JCJon Corres-Mendizabal
Jon Corres-Mendizabal
OCOnintza Carlevaris
Onintza Carlevaris
ACArkaitz Carracedo
Arkaitz Carracedo
Prostate cancer exhibits high prevalence and accounts for a high number of cancer-related deaths. The discovery and characterization of molecular determinants of aggressive prostate cancer represents an active area of research. The Immediate Early Response (IER) family of genes, which regulate Protein Phosphatase 2A (PP2A) activity, has emerged among the factors that influence cancer biology. Here, we show that the less studied member of this family, Immediate Early Response 5 like (IER5L), is upregulated in aggressive prostate cancer. Interestingly, the upregulation of IER5L expression exhibits a robust association with metastatic disease in prostate and is recapitulated in other cancer types. In line with this observation, IER5L silencing reduces foci formation, migration and invasion ability in a variety of human and murine prostate cancer cell lines. In vivo, using zebrafish and immunocompromised mouse models, we demonstrate that IER5L-silencing reduces prostate cancer tumor growth, dissemination, and metastasis. Mechanistically, we characterize the transcriptomic and proteomic landscapes of IER5L-silenced cells. This approach allowed us to identify DNA replication and monomeric G protein regulators as downstream programs of IER5L through a pathway that is consistent with the regulation of PP2A. In sum, we report the alteration of IER5L in prostate cancer and beyond and provide biological and molecular evidence of its contribution to tumor aggressiveness.

5 August 2025 in Gut
Verified
Journal Article
Open access
PDF file
MMMaria Mercado-Gómez
Maria Mercado-Gómez
NGNaroa Goikoetxea-Usandizaga
Naroa Goikoetxea-Usandizaga
AGAlvaro Eguileor Giné
Alvaro Eguileor Giné
MRMiguel A Merlos Rodrigo
Miguel A Merlos Rodrigo
MAMarta Bento Afonso
Marta Bento Afonso
Maria Luz Martinez-ChantarMaria Luz Martinez-Chantar
Maria Luz Martinez-Chantar
Background and objective: Cholangiocarcinoma (CCA) is a heterogeneous neoplasm of the biliary epithelium that easily infiltrates, metastasises and recurs. Magnesium disbalance is a hallmark of CCA, with the magnesium transporter cyclin M4 (CNNM4) being a key driver of various hepatic diseases. This study aims to unravel the role of CNNM4 in the initiation and progression of CCA. Design: CNNM4 protein and gene expression were assessed in vitro, in vivo and in patients with CCA. Silencing of CNNM4 was effectively achieved by using small interfering RNA (siRNA) or short hairpin RNA in CCA cell lines and GalNAc-conjugated siRNA in a transposon-based CCA mice model. The impact of CNNM4 on tumour cell proliferation, migration and invasion to the lungs was evaluated using the chicken chorioallantoic membrane model. Proteomic analysis was employed to elucidate the underlying molecular mechanisms. Results: CNNM4 was upregulated in CCA samples from humans, mice and cell lines. Functional studies demonstrated that CNNM4 deficiency attenuates cell growth, chemoresistance, migration, invasion, cancer stem cell properties and Warburg effect in vitro and in vivo. Proteomic analysis identified nuclear protein 1 as an upstream regulator of CNNM4-induced ferroptosis in CCA, ultimately leading to cell death. The iron chelator deferiprone could reverse the decreased proliferation induced by CNNM4 silencing, while inhibition of the heme oxygenase-1 by zinc protoporphyrin IX affected only the growth of cells with no targeted CNNM4 inhibition, highlighting the specificity of ferroptosis in CNNM4-associated effects. Conclusion: This study reveals that increased CNNM4 expression drives CCA progression and malignancy and that its inhibition may be an effective therapeutic strategy to limit proliferation and metastasis in patients with CCA.

3 June 2025 in Genome Biology
Verified
Journal Article
Open access
PDF file
NMNatalia Martin-Martin
Natalia Martin-Martin
Saioa Garcia-LongarteSaioa Garcia-Longarte
Saioa Garcia-Longarte
JCJon Corres-Mendizabal
Jon Corres-Mendizabal
ULUxue Lazcano
Uxue Lazcano
IAIanire Astobiza
Ianire Astobiza
ACArkaitz Carracedo
Arkaitz Carracedo
Metastatic hormone-naïve prostate cancer (mHNPC) is an infrequent form of this tumor type that is characterized by metastasis at the time of diagnosis and accounts for up to 50% of prostate cancer-related deaths. Despite the extensive characterization of localized and metastatic castration-resistant prostate cancer, the molecular characteristics of mHNPC remain largely unexplored. Here, we provide the first extensive transcriptomics characterization of primary tumor specimens from patients with mHNPC. We generate discovery and validation bulk and single-cell RNA-seq datasets and perform integrative computational analysis in combination with experimental studies. Our results provide unprecedented evidence of the distinctive transcriptional profile of mHNPC and identify stroma remodeling as a predominant feature of these tumors. Importantly, we discover a central role for the SRY-box transcription factor 11 (SOX11) in triggering a heterotypic communication that is associated with the acquisition of metastatic properties. Our study will constitute an invaluable resource for a profound understanding of mHNPC that can influence patient management.